Drug Approval | January 31, 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
Subscribe To Our Newsletter & Stay Updated
